

GLAXOSMITHKLINE PLC  
Form 6-K  
July 10, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4 R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 10 July 2015 that the following acquisitions of GSK Ordinary shares took place on 9 July 2015, at a price of 1370.24 pence per Ordinary share, following the re-investment of dividends on shares held within an ISA:

| Director/PDMR    | Number of Ordinary shares |
|------------------|---------------------------|
| Sir Andrew Witty | 118                       |
| Mr D S Redfern   | 22                        |
| Mrs V A Whyte    | 19                        |

| Connected Person                                    | Number of Ordinary shares |
|---|---------------------------|
| Lady C Witty (Connected Person of Sir Andrew Witty) | 23                        |

V A Whyte  
Company Secretary

10 July 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 10, 2015

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc